Monoclonal antibodies as therapeutics in human malignancies

Manjari Pandey, Daruka Mahadevan

Producción científica: Review articlerevisión exhaustiva

20 Citas (Scopus)

Resumen

Monoclonal antibodies (mAbs) are a proven effective therapeutic modality in human malignancy. Several mAbs are approved to targets critical in aberrant oncogenic signaling within tumors and their microenvironment. These targets include secreted ligands (e.g., VEGF and HGH), their receptors (e.g., HER2 and VEGFR2), cell surface counter receptors and their receptor-bound ligands (e.g., PD1 and PD1L, respectively). The ability to genetically engineer the structure and/or functions of mAbs has significantly improved their effectiveness. Furthermore, advances in gene expression profiling, proteomics, deep sequencing and deciphering of complex signaling networks have revealed novel therapeutic targets. We review target selection, approved indications and the rationale for mAb utilization in solid and hematologic malignancies. We also discuss novel mAbs in early- and late-phase clinical trials that are likely to change the natural history of disease and improve survival. The future challenge is to design mAb-based novel trial designs for diagnostics and therapeutics for human malignancies.

Idioma originalEnglish (US)
Páginas (desde-hasta)609-636
Número de páginas28
PublicaciónFuture Oncology
Volumen10
N.º4
DOI
EstadoPublished - mar 2014
Publicado de forma externa

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Huella

Profundice en los temas de investigación de 'Monoclonal antibodies as therapeutics in human malignancies'. En conjunto forman una huella única.

Citar esto